USET Tribal Epidemiology Center

Clinical Reporting System (CRS) Annual Report

Report Period	10/1/2022 - 09/30/2023	**FY 2023**
Previous Year Period	10/1/2021 - 09/30/2022	**FY 2022**
Base Period	10/1/2020 - 09/30/2021	**FY 2021**

Prepared Specifically for **USET member Tribal Nations**

USET Aggregate

Date Data Pulled 1/15/2024

This Clinical Reporting System (CRS) Annual Report is produced by USET's Epidemiology team with data from the CRS Report within RPMS. We have chosen specific metrics to highlight to display a wide variety of services. The full report is also available to you upon request. If you have questions, please email usetepi@usetinc.org.

User Population by Year



Diabetes



Diabetes Prevalence Percentage		
Difference FY 2021 to FY 2023		
User Population	↑ +0.7%	↑ +279
Male User Population	↑ +0.7%	↑ +125
Female User Population	↑ +0.7%	↑ +154

Diabetes



Diabetes Glycemic Control Percentage		
Difference FY 2021 to FY 2023		
With A1c Greater than 9 (GPRA)	-2.5%	-147
With A1c but Without Result	-0.2%	-13

Diabetes



Diabetes Blood Pressure Control		
Difference FY 2021 to FY 2023		
With Blood Pressure Documented	↑ +7.1%	↑ +490
With Controlled Blood Pressure <140/90 (GPRA)	↑ +8.4%	↑ +560

Diabetes



Diabetes: Statins, Retinal Evaluation, and Nephropathy Assessment		
Difference FY 2021 to FY 2023		
With Estimated GFR & UACR or with End Stage Renal Disease (GPRA)	↑ +3.0%	↑ +219
With Retinal Evaluation (GPRA)	↑ +2.1%	↑ +157
With Statin Prescription (GPRA)	↑ +1.6%	↑ +184

Diabetes


Diabetes Prevalence for Ages 0 to 34
100%
80%
60%
40%
20%
0%
11.0% | (N=631/5,733)
11.1% | (N=635/5,714)
11.4% | (N=639/5,623)
4.8% | (N=139/2,911)
4.6% | (N=135/2,946)
5.2% | (N=155/2,999)
2.6% | (N=89/3,460)
2.4% | (N=86/3,548)
2.3% | (N=81/3,596)
0.5% | (N=56/10,196)
0.5% | (N=51/10,029)
0.5% | (N=52/9,741)
FY 2021
FY 2022
FY 2023
<15 years
15-19 years
20-24 years
25-34 years

Diabetes


Diabetes Prevalence for Ages 35 and Older
100%
80%
60%
40%
20%
0%
57.7% | (N=1,949/3,377)
57.3% | (N=2,011/3,512)
57.5% | (N=2,117/3,682)
46.2% | (N=1,851/4,003)
46.8% | (N=1,887/4,029)
47.8% | (N=1,906/3,990)
40.7% | (N=1,666/4,092)
40.5% | (N=1,644/4,062)
41.4% | (N=1,706/4,124)
25.5% | (N=1,253/4,917)
25.7% | (N=1,289/5,016)
25.1% | (N=1,257/5,005)
FY 2021
FY 2022
FY 2023
35-44 years
45-54 years
55-64 years
65+ years

Diabetes


FY 2023 Diabetes Diagnoses by Age Range and Gender
2,500
2,000
1,500
1,000
500
0
29
23
37
44
91
64
368
271
687
570
866
840
1,016
890
1,188
929
<15 years
15-19 years
20-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65+ years
Total # Male User Pop
Total # Female User Pop


Percentage of User Population with Diabetes
with Up-to-Date Pneumococcal Vaccine
100%
80%
60%
40%
20%
0%
23.8% | (N=1,488/6,253)
25.9% | (N=1,622/6,256)
28.1% | (N=1,770/6,310)
FY 2021
FY 2022
FY 2023

Dental



Dental Services		
Difference FY 2021 to FY 2023		
With Dental Visit (GPRA)	↑ +8.4%	↑ +3263
With Intact Dental Sealants (GPRA)	↑ +2.0%	↑ +131
With Topical Fluoride Application (GPRA)	↑ +15.7%	↑ +1406

Vaccinations



Vaccinations



Influenza Vaccination				
	FY 2023		Difference FY 2021 to FY 2023	
User Population	9,632	24.9%	↑ +1147	↑ +2.9%
User Population Ages 18-49 who are High Risk	1,013	28.8%	↑ +234	↑ +6.1%
User Population Ages 65+	1,891	51.4%	↑ +415	↑ +7.7%

Influenza Vaccination by Age Group			
	FY 2021	FY 2022	FY 2023
User Population Patients	**21.9%**	**22.5%**	**24.9%**
	(N=8,485/38,689)	(N=8,757/38,856)	(N=9,632/38,760)
User Population Ages 6 months-17 years (GPRA)	**21.5%**	**21.5%**	**22.7%**
	(N=2,514/11,708)	(N=2,490/11,563)	(N=2,589/11,386)
User Population Ages 18+ (GPRAMA)	**22.3%**	**23.2%**	**26.0%**
	(N=5,885/26,350)	(N=6,183/26,648)	(N=6,975/26,811)
User Population Ages 18-49	**15.0%**	**15.2%**	**16.8%**
	(N=2,546/16,972)	(N=2,600/17,080)	(N=2,876/17,124)
User Population Ages 18-49 who are High Risk	**22.7%**	**24.4%**	**28.8%**
	(N=779/3,426)	(N=850/3,481)	(N=1,013/3,519)
User Population Ages 50-64	**31.0%**	**32.0%**	**36.8%**
	(N=1,863/6,001)	(N=1,935/6,056)	(N=2,208/6,005)
User Population Ages 65+	**43.7%**	**46.9%**	**51.4%**
	(N=1,476/3,377)	(N=1,648/3,512)	(N=1,891/3,682)

Vaccinations

Percentage of 2021 User Population with Influenza Vaccine



Percentage of 2021 User Population 18 years and older with Influenza Vaccine



Percentage of 2022 User Population with Influenza Vaccine



Percentage of 2022 User Population 18 years and older with Influenza Vaccine



Percentage of 2023 User Population with Influenza Vaccine



Percentage of 2023 User Population 18 years and older with Influenza Vaccine



Vaccinations



Vaccinations



Vaccinations



User Population 19+ (GPRA)	FY 2021	FY 2022	FY 2023	Difference FY 2021 to FY 2023
With Combination Appropriate for Age	44.9%	45.6%	47.2%	↑ +2.3%

Vaccinations



Vaccine Metrics			
Vaccines	**FY 2021**	**FY 2022**	**FY 2023**
With 4313*314 Combination (GPRA)	**59.2%**	**58.5%**	**56.0%**
	(N=430/726)	(N=402/687)	(N=398/711)
4 doses DTaP	**67.1%**	**68.6%**	**68.5%**
	(N=487/726)	(N=471/687)	(N=487/711)
3 doses Polio	**81.5%**	**80.5%**	**79.5%**
	(N=592/726)	(N=553/687)	(N=565/711)
1 dose MMR	**79.8%**	**83.0%**	**80.6%**
	(N=579/726)	(N=570/687)	(N=573/711)
3-4 doses HiB	**71.2%**	**69.3%**	**68.4%**
	(N=517/726)	(N=476/687)	(N=486/711)
3 doses Hep B	**83.3%**	**83.8%**	**83.3%**
	(N=605/726)	(N=576/687)	(N=592/711)
1 dose Varicella	**79.5%**	**83.3%**	**80.5%**
	(N=577/726)	(N=572/687)	(N=572/711)
4 doses Pneumococcal	**65.8%**	**63.6%**	**62.6%**
	(N=478/726)	(N=437/687)	(N=445/711)

Vaccinations





Cancer





Cancer Screening	
Difference FY 2021 to FY 2023	
With Pap Smear in 3 yrs / Pap+HPV in 5yrs / HPV Primary in 5yrs (GPRA)	-3.2%
With Mammogram w/in 2 years (GPRA)	+5.0%
With CRC Screening (GPRA)	-0.8%

Tobacco


Percentage of User Population Ages 5 and Older who Received Tobacco Screening
100%
80%
60%
40%
20%
0%
53.5% | (N=19,009/35,547)
31.6% | (N=6,010/19,009)
10.3% | (N=1,963/19,009)
58.2% | (N=20,827/35,763)
29.8% | (N=6,204/20,827)
10.5% | (N=2,182/20,827)
62.3% | (N=22,288/35,764)
28.2% | (N=6,289/22,288)
9.2% | (N=2,051/22,288)
FY 2021
FY 2022
FY 2023
with Tobacco Screening
Tobacco Users
with Exposed to ETS/Smoker in home


Percentage of User Population Ages 5 and Older who Received Tobacco Screening by Gender
100%
80%
60%
40%
20%
0%
56.9% | (N=10,494/18,451)
61.6% | (N=11,440/18,580)
65.8% | (N=12,260/18,628)
49.8% | (N=8,515/17,096)
54.6% | (N=9,387/17,183)
58.5% | (N=10,028/17,136)
FY 2021
FY 2022
FY 2023
Male User Population 5+
Female User Population 5+


Percentage of User Population Tobacco Users who Received Counseling or Quit
100%
80%
60%
40%
20%
0%
33.2% | (N=3,784/11,391)
35.3% | (N=3,954/11,216)
40.1% | (N=4,451/11,086)
FY 2021
FY 2022
FY 2023
with Tobacco Cessation Counseling, Rx for Cessation Aid, or Quit(GPRA)

Tobacco


Number of User Population Tobacco Users who Quit by Year
700
600
500
400
300
200
100
0
(N=543/11,391)
(N=506/11,216)
(N=583/11,086)
FY 2021
FY 2022
FY 2023


Number of User Population Tobacco Users who Quit by Year and Age
700
600
500
400
300
200
100
0
0
5
538
0
11
495
0
8
575
FY 2021
FY 2022
FY 2023
<12 years
12-17 years
18+ years

Alcohol







Alcohol Screening	Difference FY 2021 to FY 2023
User Population Ages 9-75 (GPRA)	+8.1%
User Population Ages 9-17	+12.3%
User Population Ages 18-75	+7.0%

Substance Use







Substance Use Metrics				
	FY 2021	**FY 2022**	**FY 2023**	**Difference FY 2021 to FY 2023**
User Population Ages 12+ (GPRA Dev) With Substance Screen or Diagnosis	**6.2%**	**6.2%**	**6.1%**	-0.1%
	(N=1,906/30,670)	(N=1,926/31,012)	(N=1,909/31,185)	
User Population Ages 12+ with Substance Screening With Positive Substance Screen	**88.8%**	**93.1%**	**92.4%**	+3.6%
	(N=1,692/1,906)	(N=1,794/1,926)	(N=1,763/1,909)	

Depression, Suicide and Mood Disorder





Depression, Suicide and Mood Disorder



Difference FY 2021 to FY 2023	
With Suicide Risk Assessment	+10.6%
With 12-Week Treatment Medications (GPRA)	+6.9%
With 180-Day Treatment Medications (GPRA)	+4.4%

Depression, Suicide and Mood Disorder



Mood Disorder Metrics				
	FY 2021	**FY 2022**	**FY 2023**	**Difference FY 2021 to FY 2023**
User Population Ages 12-17 (GPRA)				
With Depression Screening or Mood Disorder Diagnosis (GPRA)	**49.2%** (N=2,126/4,320)	**55.6%** (N=2,425/4,364)	**59.7%** (N=2,612/4,374)	↑ +10.5%
With Mood Disorder Diagnosis	**11.4%** (N=243/2,126)	**9.7%** (N=236/2,425)	**11.1%** (N=290/2,612)	↓ -0.3%
User Population Ages 18+ (GPRA)				
With Depression Screening or Mood Disorder Diagnosis (GPRA)	**57.8%** (N=15,218/26,350)	**61.9%** (N=16,505/26,648)	**63.1%** (N=16,927/26,811)	↑ +5.3%
With Mood Disorder Diagnosis	**13.5%** (N=2,058/15,218)	**9.4%** (N=1,551/16,505)	**9.0%** (N=1,530/16,927)	↓ -4.5%

Depression, Suicide and Mood Disorder

Percentage of User Population Screened for Mood Disorder and Results for 2021 User Population 12-17 (GPRA)



Percentage of User Population Screened for Mood Disorder and Results for 2021 User Population 18+ (GPRA)



Percentage of User Population Screened for Mood Disorder and Results for 2022 User Population 12-17 (GPRA)



Percentage of User Population Screened for Mood Disorder and Results for 2022 User Population 18+ (GPRA)



Percentage of User Population Screened for Mood Disorder and Results for 2023 User Population 12-17 (GPRA)



Percentage of User Population Screened for Mood Disorder and Results for 2023 User Population 18+ (GPRA)



Intimate Partner Violence



Metrics	
	Difference FY 2021 to FY 2023
With Initimate Partner Violence/Domestic Violence Screening (GPRAMA)	↑ +7.6%

BMI, Obesity and Exercise



User Population Ages 2-74				
	FY 2021	**FY 2022**	**FY 2023**	**Difference FY 2021 to FY 2023**
With BMI Calculated	**60.5%**	**61.7%**	**64.8%**	+4.3%
	(N=21,855/36,108)	(N=22,382/36,278)	(N=23,418/36,154)	

BMI, Obesity and Exercise



Exercise Metrics	
User Population Ages 5+	**Difference FY 2021 to FY 2023**
With Physical Activity Assessment	↑ +10.7%
With Exercise Education	↑ +4.0%
With Exercise Goal	↓ -0.1%

BMI, Obesity and Exercise

Percentage of User Population with a Body Mass Index Calculated and their Weight Classification for 2021



Percentage of User Population with a Body Mass Index Calculated and their Weight Classification for 2022



Percentage of User Population with a Body Mass Index Calculated and their Weight Classification for 2023



Cardiovascular





Cardiovascular



User Population Ages 18+ with Stroke, Transient Ischemic Attack and Atrial Fibrulation				
	FY 2021	**FY 2022**	**FY 2023**	**Difference FY 2021 to FY 2023**
With Anticoagulant Prescription	**50.0%**	**51.6%**	**49.3%**	-0.8%
	(N=28/56)	(N=33/64)	(N=33/67)	

HIV, STI, and Hepatitis C





HIV, STI, and Hepatitis C





HIV, STI, and Hepatitis C





STI Screenings	Difference FY 2021 to FY 2023
User Population Ages 13+ with Syphilis Screening	↑ +0.0%
Male User Population Ages 13+ with Syphilis Screening	↑ +0.1%
Female User Population Ages 13+ with Syphilis Screening	↓ -0.0%
With Chlamydia Screen (Female Ages 16-29 years)	↑ +2.0%

Asthma



Asthma Metrics				
With Asthma	**FY 2021**	**FY 2022**	**FY 2023**	**Difference FY 2021 to FY 2023**
	3.2%	3.6%	3.7%	+0.6%

Medication/Education





Medication/Education





Annual Wellness Exam



Medications/Screenings Difference By Years	Difference FY 2021 to FY 2023
Receiving Medication Education	+4.0%
Active Clinical Patients Ages 65+ with Annual Wellness Visit	-0.7%
Male Active Clinical Patients Ages 65+ with Annual Wellness Visit	-0.9%
Female Active Clinical Patients Ages 65+ with Annual Wellness Visit	-0.5%
With Patient Education	-1.2%

Elders


Number of Active Clinical Patients Ages 65 and Older who are Exposed to At Least One High Risk Medication
700
600
500
400
300
200
100
0
560
589
659
205
199
225
34
30
44
65 - 74 years
75 - 84 years
85+ years
FY 2021
FY 2022
FY 2023


Percentage of Active Clinical Patients Ages 55 and Older who Received Functional Status Screening
100%
80%
60%
40%
20%
0%
31.5% | (N=1,953/6,197)
34.2% | (N=2,130/6,221)
37.8% | (N=2,428/6,431)
FY 2021
FY 2022
FY 2023
w/ Functional Status Screening

Elders


Percentage of User Population Ages 65 and Older with Fall Screening Results
100%
80%
60%
40%
20%
0%
72.1% | (N=857/1,188)
73.9% | (N=1,027/1,390)
77.2% | (N=1,223/1,585)
26.4% | (N=314/1,188)
23.1% | (N=321/1,390)
20.6% | (N=327/1,585)
16.6% | (N=197/1,188)
14.9% | (N=207/1,390)
14.3% | (N=226/1,585)
6.5% | (N=56/1,188)
8.6% | (N=88/1,390)
7.0% | (N=86/1,585)
FY 2021
FY 2022
FY 2023
With Fall Risk Screen
With History of Fall
With Fall Injury
With Abnormal Gait

Elders

Elder Metrics	
Screenings	**Difference FY 2021 to FY 2023**
Active Clinical Patients Ages 55+ with Functional Status Screening	↑ +6.2%
User Population Ages 65+ with Fall Risk Screen or Diagnosis	↑ +7.9%
User Population Ages 65+ with History of Fall	↑ +0.5%
User Population Ages 65+ with Fall Injury	↓ -2.3%
User Population Ages 65+ with Abnormal Gait	↓ -5.8%